---
title: "Understanding the Market | INNOVENT BIO once rose nearly 5% and will officially turn blue starting from December 8"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/267096308.md"
description: "INNOVENT BIO once rose nearly 5%, and as of the time of publication, it is up 3.9%, trading at HKD 90.65, with a transaction volume of HKD 177 million. On the news front, on November 21, the results of the Hang Seng Index series quarterly review were released, and all changes will take effect from December 8, 2025. Among them, INNOVENT BIO will be included in the Hang Seng Index constituent stocks, increasing the number of constituent stocks from 88 to 89. It is worth mentioning that on November 20, INNOVENT BIO announced that the phase III clinical study (GLORY-2) of Masitide injection (glucagon [GCG] / glucagon-like peptide-1 [GLP-1] dual receptor agonist, research code: IBI362) conducted in the Chinese population with moderate to severe obesity has achieved its primary endpoint and all key secondary endpoints. INNOVENT BIO will soon submit a new drug application for Masitide 9mg for adult weight control to regulatory authorities"
datetime: "2025-11-24T01:43:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/267096308.md)
  - [en](https://longbridge.com/en/news/267096308.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/267096308.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/267096308.md) | [繁體中文](https://longbridge.com/zh-HK/news/267096308.md)


# Understanding the Market | INNOVENT BIO once rose nearly 5% and will officially turn blue starting from December 8

According to Zhitong Finance APP, INNOVENT BIO (01801) once rose nearly 5%, and as of the time of writing, it is up 3.9%, trading at HKD 90.65, with a transaction volume of HKD 177 million.

On the news front, on November 21, the results of the Hang Seng Index series quarterly review were released, and all changes will take effect from December 8, 2025. Among them, INNOVENT BIO will be included in the Hang Seng Index constituent stocks, increasing the number of constituent stocks from 88 to 89.

It is worth mentioning that on November 20, INNOVENT BIO announced that the phase III clinical study (GLORY-2) of Masitide peptide injection (glucagon \[GCG\] / glucagon-like peptide-1 \[GLP-1\] dual receptor agonist, research code: IBI362) conducted in the Chinese population with moderate to severe obesity has achieved its primary endpoint and all key secondary endpoints. INNOVENT BIO will soon submit a new drug application to regulatory authorities for Masitide peptide 9mg for adult weight control

### Related Stocks

- [INNOVENT BIO (01801.HK)](https://longbridge.com/en/quote/01801.HK.md)

## Related News & Research

- [Innovent Biologics posts FY profit RMB813.6 million](https://longbridge.com/en/news/280626112.md)
- [Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD](https://longbridge.com/en/news/280236866.md)
- [Yunnan Baiyao Gets Nod to Trial INB301 Injection](https://longbridge.com/en/news/281464510.md)
- [Innovent Bio's Tabosun Gets China Nod as Pre-treatment for Colon Cancer](https://longbridge.com/en/news/270943961.md)
- [Innovent Biologics' Q4 Revenue Surges 60%](https://longbridge.com/en/news/274820825.md)